The association of bariatric surgery and specialized medical obesity treatment with beneficial and detrimental outcomes remains uncertain.
O besity is associated with increased morbidity and mortality due to cardiometabolic disease, cancer, and mental disorders.
1,2 Current treatment options for severe obesity encompass medical therapy and bariatric surgery. 3 Intensive lifestyle intervention is associated with 5% to 8% weight loss and improvement of cardiovascular risk factors, 4, 5 while bariatric surgery is associated with larger weight loss and medium-to long-term (1-to 5-year) remission of hypertension, type 2 diabetes, and dyslipidemia. [6] [7] [8] [9] Bariatric surgery is associated with a number of somatic and mental complications, but few studies report long-term complication rates. 6, 10 Pragmatic studies comparing clinical outcomes after surgical and medical treatment may complement randomized explanatory trials by providing data that may help clinicians and patients make shared decisions about treatment choice. 11 To our knowledge, no large-scale clinical practice-based study has compared the long-term association of bariatric surgery and specialized medical obesity treatment with obesity-related somatic and mental comorbidities, nor their respective complication rates. 6, 12 In a publicly funded tertiary care setting, this study aimed to compare the long-term outcomes of bariatric surgery and specialized medical obesity treatment. It was hypothesized that, as compared with medical therapy, bariatric surgery would be associated with higher rates of remission, and lower rates of new-onset drug-treated hypertension, diabetes, and dyslipidemia, at the expense of higher medical, mental, and surgical complication rates.
Methods

Study Design
This registry-based cohort study conducted at Vestfold Hospital Trust, Norway, was designed to compare changes in drugtreated obesity-related comorbidities among patients with severe obesity (body mass index [BMI, calculated as weight in kilograms divided by height in meters squared] ≥40 or BMI ≥35 and at least 1 obesity-related comorbidity) undergoing bariatric surgery or specialized medical obesity treatment. Baseline data were collected from the Registry-and Biobank (RB) study, which contains complete clinical and laboratory information from all included patients at their first consultation at the center. 13 The RB study was approved by the Regional Committee for Medical and Health Research Ethics (reference No. S-05175), 13 and the present study, including retrieval of data from 
Setting
The Morbid Obesity Center is a publicly funded tertiary care center, accredited by the European Association for the Study of Obesity as an EASO Collaborating Centre for Obesity Management, 14 providing both specialized medical and surgical obesity treatment. In the present study, the physicians informed the patients about beneficial and detrimental effects of various treatment options and encouraged the patients to incorporate their own values and preferences in the decision-making process before the patient and physician agreed on the specific choice of therapy: medical therapy or bariatric surgery. 15 Patients who opted for medical treatment could choose between individual-or group-based programs, either in the outpatient clinic or at a rehabilitation center. The rehabilitation centers offered multidisciplinary intensive lifestyle intervention programs as previously reported (eAppendix 1 in the Supplement). 16, 17 Patients were offered clinical follow-up at the tertiary clinic for at least 2 years after finishing the surgical or medical treatment programs.
Participants
Consecutive treatment-seeking patients referred to a tertiary care center were informed about the research question before giving their written informed consent and before collection of baseline and follow-up data. Those patients enrolled in the RB study from November 2005 until July 2010 were informed by letter about the present follow-up study, and they were given the choice of declining participation. Information on treatment choice was obtained from electronic patient records in July 2015, and information on drugs was obtained from the NorPD in June 2016. The NorPD contains information on all prescribed drugs dispensed from pharmacies to patients living outside institutions and data on all-cause mortality from the National Registry. 18 Anonymous data on medical complications and surgical procedures were obtained from the Norwegian Patient Registry from 2008 to 2015. 19 Laboratory follow-up data were obtained from the laboratory files of Vestfold Hospital Trust. The physician completed the standard registry questionnaire regarding race by fixed categories (white: yes or no). This variable was included to show the predominance of white patients, which reflects the Norwegian population (>90% white).
while start of surgical treatment was the operation date. Comorbidities were defined according to their respective Anatomical Therapeutic Chemical (ATC) codes and defined as present in patients who had dispensed at least 1 prescribed drug the year before treatment and within each year of follow-up (eTable 1 in the Supplement). Dispensing of specific drugs (yes/no) from the year before start of treatment was used to categorize each patient as an initial user or nonuser of a given drug. The prevalence of specific comorbidities was defined as the proportion of patients who were dispensed a drug from the defined ATC codes. Patients who no longer received drugs related to a specific comorbidity were categorized as having remission, while those who had a drug dispensed for the first time were categorized as having new-onset comorbidity. Medical complications and surgical procedures were defined according to International Statistical Classification of Diseases and Related Health Problems, Tenth Revision and NOMESCO Classification of Surgical Procedures (eTable 2 in the Supplement).
The proportion of patients with anemia, hypoproteinemia, and vitamin and mineral deficiencies more than 3 months after the start of treatment were assessed in a subgroup of patients with available laboratory results. Detailed methods for baseline measurements in the database are described elsewhere. 16 The end of follow-up was December 31, 2015, or death, whichever came first.
Study Size
It was estimated that the proportions of patients with remission of hypertension at 5 years (primary outcome) would be 35% and 15% in the surgical and medical group, respectively, and the basis for these assumptions is found in the trial protocol (eAppendix 2 in the Supplement). 15, 16 To achieve power greater than 85%, 170 patients with baseline hypertension should be followed up for 5 years or more. However, the final sample size was much larger, resulting in a post-hoc power greater than 99% (Table 1) .
Statistical Analysis
Crude comparisons between groups were performed using independent-samples t test, Mann-Whitney Wilcoxon test, or χ 2 test as appropriate. To assess possible differences between treatment groups when all measurements were considered, binary logistic regressions were applied using mixed models for repeated measures. Possible confounders (age, sex, and BMI at baseline) and an interaction term group by time were initially included into the models. However, the latter was not statistically significant so group by time was removed from the models to increase precision in the remaining estimates. As patients with higher BMI tend to opt for bariatric surgery, 15 and to minimize selection bias, BMI was included in the multivariable models. Two models for each selected drug code modeling remission and new onset were fitted separately. Odds ratios were transformed to relative risk (RRs) with 95% CIs, as suggested by Zhang and Yu, 20 and comparative absolute rates and weighted risk differences are presented for most outcomes. Overall incidence was estimated as a weighted average of all the yearly incidences. The weights used to transform odds ratios to RRs were constructed as proportions of individuals foll o w e du pa tag i v e np o i n t .Se n s i t i vi t ya n a l y s e sw e r ep e rformed, excluding either those who did not undergo gastric bypass (n = 77), the outpatient group (n = 492), or the rehabilitation center group (n = 464). The analyses were not adjusted for multiple testing, but P values less than .01 were considered statistically significant. Therefore, except for the primary outcomes, the study findings should be considered exploratory. All tests were 2-sided. All analyses were performed using SPSS version 22 (SPSS Inc) and Stata version 9 (StataCorp).
Results
Participant Characteristics
A total of 2109 consecutive patients with severe obesity were assessed for eligibility. After the exclusion of 221 patients, including 107 medically treated patients who later underwent bariatric surgery, complete data from 1888 patients were included in the prespecified analyses ( Figure 1 ). A total of 956 patients (51%) voluntarily opted for specialized medical treatment, while 932 patients (49%) voluntarily opted for bariatric surgery, mostly gastric bypass (92%) or sleeve gastrectomy (7%). At baseline, the patients had a mean (SD) age of 43.5 (12.3) years and BMI of 44.2 (6.1) (66% were women). As compared with medical patients, surgically treated patients were significantly younger with a higher BMI and earlier debut of obesity (Table 1 ). The patients were followed up for a median of 6.5 years (range, 0.2-10.1 years) after the start of treatment, and the mean (SD) time from the first consultation to surgery was 23 (12) months. The total median follow-up durations in the medical and surgical treatment groups were 7.1 years (range, 0.2-10.1 years) and 7.8 years (range, 2.5-10.0 years), respectively, and the median follow-up after the bariatric surgical procedure was 5.8 years (range, 0.6-9.2 years).
Prevalence of Obesity-Related Comorbidities
At the start of treatment, the proportions of patients treated with drugs for hypertension (48%), diabetes (26%), dyslipidemia (21%), depression (21%), or anxiety and sleep disorders (26%) did not differ significantly between treatment groups, while the proportion of opioid users was significantly higher in the surgical group (Table 1) .
The prevalences of hypertension, diabetes, and dyslipidemia after treatment start were significantly lower in the surgical group than in the medical group (all P < .001; Figure 2 ). By contrast, the prevalences of depression and opioid use were significantly higher in the surgical group (P = .004 and P < .001, respectively) while the prevalence of anxiety and sleep disorders did not differ significantly between groups (P = .02; Figure 2 ). Table 2 ). (Figure 3 and Figure 4 , Table 2 ).
Primary Outcomes
Prespecified Secondary Outcomes
Adverse Events
The surgical patients had higher risk of several complications and surgical procedures: for example, at least 1 additional gastrointestinal surgical procedure (AR, 31 Blood test results more than 3 months after treatment start demonstrated an increasing proportion of patients with anemia, hypocalcemia, and hypoalbuminemia, but with no significant differences between groups. However, the proportion of patients with low ferritin levels was significantly higher in the surgical group (26% vs 12%, P < .001) (eTable 4 in the Supplement).
A total of 26 (2.8%) and 65 (6.8%) patients in the surgical and medical groups died (eFigure in the Supplement), with no significant (age, sex, and BMI-adjusted) differences in overall mortality risk (hazard ratio, 0.74; 95% CI, 0.45-1. 19 ). The 30-day mortality after surgery was zero.
Sensitivity Analysis
A sensitivity analysis of data from NorPD, excluding either those who did not undergo gastric bypass (n = 77), the outpatient group (n = 492), or the rehabilitation center group (n = 464), did not substantially change the main findings (eTable 5 in the Supplement). However, the association of bariatric surgery with remission of hypertension decreased from an RR of 2.1 (95% CI, 2.0-2.2) to 1.4 (95% CI, 1.1-1.7) after exclusion of the outpatient group.
Discussion
Among patients with severe obesity followed up for a median of 6.5 years, bariatric surgery compared with medical treatment was associated with a clinically important increased risk for complications, as well as lower risks of obesity-related metabolic comorbidities. Bariatric surgery was associated with higher risk of remission of hypertension (RD, 19.5%) and lower risk of new-onset hypertension (RD, 8.7%). Surgically treated Table 2) . The risk for complications should be considered in the decision-making process. The beneficial effects of bariatric surgery are well known, but the present study adds knowledge about the totality of short-to long-term medical outcomes from a large number of patients with morbid obesity who underwent specialized treatment at a tertiary care center. The findings cannot, however, be directly compared with previous studies lacking control groups or that included control groups receiving routine clinical care or no active treatment at all. The associations between bariatric surgery and remission and prevention of hypertension 12 are consistent with the results from 2 nonrandomized clinical studies 16, 21 and some observational studies. [22] [23] [24] Similarly, the strong association between bariatric surgery and the remission and prevention of diabetes confirms and extends findings from randomized and observational studies. 7, 8, [24] [25] [26] Although few studies have specifically compared changes in dyslipidemia as judged by statin therapy, 12 the beneficial association between surgical treatment and dyslipidemia is consistent with results from previous studies ( Figure 3) . 23, 27 A recent meta-analysis showed that bariatric surgery was associated with postoperative decreases in the prevalence of depression, while limited evidence suggested that this improvement may not be maintained beyond the first years after surgery. 10, 28, 29 However, the present study did not show any significant decline in the prevalence of drug-treated depression after treatment start in either group, while patients undergoing surgery had significantly higher risk of newonset depression (RD, 2.4%) ( Figure 2 and Figure 4) . A large US multicenter cohort study recently reported a significant increase in the prevalence of opioid users after a Relative risk ratios were converted from adjusted odds ratios derived from multiple logistic regression models for repeated measurements. 20 The analyses were adjusted for sex, age, and body mass index at baseline. The absolute risk for each condition was calculated as a weighted average of incidences of all the yearly incidences available. The weights were constructed as proportions of individuals followed up at a given point. Risk differences were calculated as the difference between weighted incidences using data from the whole follow-up. bariatric surgery (14.7% to 20.3%). 30 In contrast, the present study showed a higher prevalence of opioid users before surgery (36.4%), while the prevalence did not increase significantly after surgery ( Figure 2) . However, surgical patients had a slightly higher risk of new-onset opioid prescriptions after surgery (RD, 3.6%). The high prevalence of opioid prescriptions in the nonsurgical group indicates that obesity itself may be a risk factor for opioid use. Recent evidence indicates that abdominal pain is common after gastric bypass, with a prevalence between 22% and 34% for 3 to 5 years after bariatric surgery. [31] [32] [33] The present study supports and extends these findings, as 26.1% and 5.4% of patients in the surgical group were medically or surgically treated for abdominal pain, respectively, as compared with 13.5% and 0.4% of patients in the group who underwent specialized medical treatment.
A substantial number of patients underwent any gastrointestinal surgery, both after surgical and medical treatment (31.3% vs 15.5%), the former in line with a recent report from the Scandinavian Obesity Surgery Registry showing a rate of gastrointestinal surgery of 24.4% (median follow-up, 3.6 years) after gastric bypass. 34, 35 Most surgical complications were caused by intestinal obstruction (8.7%), gallbladder disease (8.1%), and abdominal pain (5.4%). However, the relatively high prevalence of gastrointestinal surgery in the medically treated group probably reflects that obesity by itself may be associated with gastrointestinal diseases and symptoms.
Strengths
Strengths of this study include a nearly 100% follow-up rate on both serious complications and dispensed drugs for comorbidities, and high external validity and generalizability to similar treatment programs in publicly funded health care systems.
Limitations
This study has several limitations. First, age and baseline BMI, both probably associated with the primary outcomes, differed significantly between treatment groups, and patients with higher BMI levels and younger age were more likely to undergo bariatric surgery. Accordingly, selection bias and confounding by indication might have reduced the internal validity of the study. These differences were, however, minimized by adjustments for age and BMI in the multivariable analyses. In addition, unknown differences between groups might have biased the results. Second, the use of dispensed drugs as proxy outcomes for the various comorbidities might have underestimated the proportions of patients with comorbidities. However, this limitation may not have altered the absolute differences between the groups. Third, this study did not address other outcomes, such as weight loss, quality of life, or cardiovascular events, and it had insufficient power to compare mortality. The lack of weight loss data is a major limitation, as differences in weight loss might have mediated the associations between treatment and outcomes. Fourth, 107 patients who initially opted for medical treatment were excluded owing to later bariatric surgery. Fifth, medical treatment does not primarily intend to resolve comorbidities, but rather to improve somatic and mental health and/or relieve symptoms, and a number of drugs have shown beneficial effects on cardiovascular morbidity and mortality. 36-39 Nevertheless, most bariatric surgery candidates expect improvement and prevention of obesity-related comorbidities after bariatric surgery. 40 Sixth, only a minority (7%) of the surgical patients underwent sleeve gastrectomy, and the results might not be generalizable to patients undergoing this procedure. Seventh, laboratory data were exploratory and incomplete. Eighth, this study included treatment-seeking white patients with severe obesity, limiting the generalizability of the results to populations with other races/ethnicities, less severe obesity, or people not seeking treatment.
Conclusions
Among patients with severe obesity followed up for a median of 6.5 years, bariatric surgery compared with medical treatment was associated with a clinically important increased risk for complications, as well as lower risks of obesity-related comorbidities. The risk for complications should be considered in the decision-making process.
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Outpatient treatment at the Morbid Obesity Center at Vestfold Hospital Trust
All patients were examined by a medical doctor at their first visit to the center, and subsequently they were offered at least one consultation with a dietician, a physiotherapist, and a trained "obesity" nurse.
During a second consultation with the doctor (3-6 months after the first), the patient and the doctor agreed on an individually tailored 1-year treatment program, but all patients were offered at least 2- reducing measures, as well as give estimates of treatment length, differences in usage, problematic usage of different medicines and usage of more than one medicine.
Research Question and hypotheses
The main purpose of this study is, in combination with data from the Register and Biobank study and follow-up data from the Norwegian Prescription Database, to compare the longterm effects (4-10 years) of surgical and non-surgical treatment of morbid obesity on obesity related comorbidities by studying changes in medicine usage after treatment.
Hypotheses
1. Primary hypothesis: As compared to non-surgical treatment, bariatric surgery will be associated with higher rates of remission, and lower rates of new-onset drug treated hypertension during a follow-up period of ≤ 10 years.
Secondary hypotheses:
Changes in the usage of other drugs, particularly drugs related to obesity related comorbidities, will differ significantly between patients undergoing bariatric surgery or non-surgical treatment during the follow-up period.
Participants and study design
In The Norwegian Prescription Database is not explicitly mentioned in the information and consent letter each patient signed. Using data from this database must therefore fulfil the register's prerequisite of anonymity. To what extent a data set actually fulfils this demand for anonymity depends upon a specific assessment, which in most cases, the Prescription Database is best suited to give. We will thus apply to the Norwegian Data Protection Agency for a concession to make a pseudonym association between selected data from the MOC © 2017 American Medical Association. All rights reserved.
Register and Biobank study and the Prescription database. See the chapter on "Ethics and protection of identifiable personal details" for more information on how we will inform patients about the project and the association with data from the Norwegian Prescription Database.
We are of the opinion that the data set which we wish to associate with the Prescription Database will meet the demand of anonymity after the data set is collated (see 
Dataset and variables
The primary endpoint is change in the usage of antihypertensive medicines during the 4-10 years post treatment for morbid obesity. Treatment groups will be compared (surgical or conservative treatment) with consideration given to the cumulative number of patients who cease/begin to use blood pressure medicines, as well as changes in the number and type of medicines taken. As an extension of this, we also wish to compare changes in the usage of other drugs related to obesity or obesity related comorbidities.
The MOC's Register and biobank study includes, amongst other things, data on medicine usage, comorbidities and weight, and will be used as a source of baseline data. The database is updated with treatment choice and operation date for those patients registered by July 2010. This data was retrieved from patient journals and was registered in May 2013.
We wish to associate the following variables from the Register and Biobank study with the We are of the opinion that the data set which we wish to associate with data from the prescription database contains neither directly nor indirectly identifiable data due to the amount and type of variables, making the identification of patients simply unworkable. We would also stress both that the transfer of the research files will go to researchers, and not previous treatment givers or surgeons, as well as that LETMO is a stand-alone research project with a short project timeframe, with data from the prescription database not being traced back to the Register and Biobank study.
Data on medicine usage is prospectively registered in the prescription database, and will be associated, upon successful application, with data from the Register and Biobank study for each individual in the period 2005-2015. The prescription database will also give both date of the year and month of death, such that patients who are dead are not coded as having ceased using all medication.
Statistics and sample size
Two previous studies have shown that over half of patients undergoing bariatric surgery cease using anti-hypertensive medicines after one to two years (25, 32) . Intensive lifestyle intervention in patients with obesity and type 2 diabetes in the Look AHEAD-study was associated with 8% 1-year weight loss, but no statistically significant change in the proportion of patients who used anti-hypertensive medicines was shown (33). By contrast, 23% of patients had remission of hypertension one year after lifestyle intervention and a similar weight loss in the "Morbid Obesity treatment, Bariatric surgery versus Intensive Lifestyle intervention (MOBIL) study (26) . The prevalence of anti-hypertension medication use in a previous cross-sectional study of 505 patients with morbid obesity from our group was 32% (n=79) in the group operated upon, and 35% (n=89) in the group which underwent lifestyle intervention (31) . In the absence of relevant long-term data, we base the power calculations on extrapolation of data from the MOBIL study and speculate that 35% of patients in the surgical group and 15% of patients in the lifestyle intervention group may be off blood pressure medication after five years. If the 505 patients from our previous cross-sectional study are followed for 5-years, the present study has a power of more than 85% to reveal a difference between groups of 20% (35% vs. 15%) as given above (alfa 0,05) (34).
The results will be analysed using SPSS 21.0 and STATA SE v 10. The change in the usage of medicines will be analysed using longitudinal models. We will analyse at baseline patients treated with medicines, while those patients who did not receive medicinal treatment will each have an individual baseline, looking at the cessation of medicine usage and the start of © 2017 American Medical Association. All rights reserved.
medicine usage. We will use landmark-analysis to pinpoint the time at which medicine usage resumed in those patients who stopped using medicine after treatment for morbid obesity, as well as in those patients who did not use medicine in the first, second or a specified number of years after treatment. In addition, we will plot cumulative hazard curves which will show the difference between the surgical and non-surgical treatment groups, in addition to other chosen covariates.
The two patient groups, those who underwent an operation for morbid obesity and those who received non-surgical treatment, are similar in terms of most background variables except age, period of overweight and weight (35) . These variables will be included as covariates (possible confounding factors) in our longitudinal models.
Ethics and the protection of personal identification information
All patients included in this study have given their written consent allowing data from the Register and Biobank to be used in research which investigates, amongst other things,
whether "Surgical treatment of morbid obesity is better than non-surgical treatment in terms of the prevention and improvement of comorbidities". Permission was also given allowing, when needed, the cross-checking of information in the database with that from the patient record. The information can be stored for up to 20 years for use in later research, with consent given allowing data to be associated with other registers (such as the Cancer
Registry of Norway and the Norwegian Cause of Death Registry).
As has been previously discussed, the prescription database is not explicitly mentioned in the consent form patients signed. An association between data from the prescription database must therefore satisfy the prescription register's prerequisite of anonymity. To what extent a data set actually fulfils this prerequisite depends upon a specific assessment, which in most cases, the Prescription Database is best suited to make. We are, nevertheless, of the opinion that the data set which we wish to associate with the prescription register contains neither directly nor indirectly identifiable data due to the amount and type of variables, making the identification of patients simply unworkable. We would also stress both that the transfer of the research file will go to researchers, and not previous treatment givers or surgeons, as well as that LETMO is a stand-alone research project with a short project timeframe, with data from the prescription database not being traced back to the Register and biobank study. In addition, patients will be informed by letter and on the MOC website about the study and the association with data from the Prescription Database.
© 2017 American Medical Association. All rights reserved.
All information received in connection with this study will be treated with the strictest confidentiality. Confidential information from the patient journal will be stored in the hospital's journal system, which is protected and all updates are logged.
When information is taken from the journal system and added to the database patients will be made anonymous, with only the project leader having the means of identifying individual patients. The study encompasses many patients recruited over a long time period, and the variables registered are general and applicable to many of the patients. It will thus not be possible to identify each patient on the basis of the published results.
The LETMO-project will be registered with the Norwegian Centre for Research Data, and a concession will be applied for with the Data Protection Authority. When this concession is granted, a further application will be lodged with the Norwegian Institute of Public Health in order to access data from the Prescription database.
All data will be stored locally on a secure research server at Vestfold Hospital Trust. The main concern is that sensitive information should be transferred safely, with the server protected against unauthorised access, misuse and damage.
The associated research file used in this project, which uses health details from the Register and Biobank study and the Prescription Database, cannot be retraced to the Register and Biobank study. Vestfold Hospital Trust, in the form of the administrative director, is responsible for data protection.
The Project's Scientific Importance
The results from this cohort of approximately 2000 treatment-seeking patients with morbid obesity undergoing different conservative and surgical programmes for lasting health behavioural changes have a relatively high external validity and generalizability. The study can therefore give clinically valuable information which can improve the future treatment choices of treatment seeking Nordic patients with morbid obesity, and, moreover, can contribute in the future to more individualised patient-specific treatment. Previously published data on the effect of morbid obesity treatment on high blood pressure has given diverging results, with the present study therefore able to improve our understanding of this topic. One of the study's strengths is that it compares two groups who have undergone different treatment for the same illness, as well as the fact that it is a consecutive study at one centre, that it has a long follow-up and prospectively collected follow-up data. The study's weaknesses are that it lacks the follow-up data on weight development as an explanatory variable, and cannot therefore be used to explore the question of comorbidities which are not © 2017 American Medical Association. All rights reserved.
treated medically (for example, obstructive sleep apnoea and diet-regulated type 2 diabetes).
These two groups have different baselines with respect to age, weight and period of overweight (35) . There is, however, for the first 500 patients in the register, no statistically significant difference in the prevalence of comorbidity or medicine usage for the different comorbidities (31) . The study results will be both published in international peer-assessed journals and presented at national and international conferences.
Plan of Work
This study is a part of Gunn Signe Jakobsen's PhD project, which is scheduled to be 
Financing
Up to and including 2013, Vestfold Hospital Trust and the MOC have given research grants and research funding to PhD candidates. The aforementioned candidate has received a wage from Vestfold Hospital Trust for a further 6 months. We will apply for external funding 
